FDA Approves Moderna, Pfizer’s Booster Shots – Is Now the Time to Buy the Stocks?

Happy young man showing thumb up and his arm after vaccination.
Chalabala / Getty Images/iStockphoto

In a widely anticipated move, and following several countries’ earlier approval, the Food and Drug Administration approved the use of Pfizer and Moderna booster shots today, for certain immunocompromised individuals, specifically, solid organ transplant recipients or those who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.

See: Need To Prove You’re Vaccinated? Here’s How To Add Your COVID-19 Card To Your Phone
Find: The Best Resources for Financial Help Post-COVID-19

The approval for the third shot will bring in billions for both pharmaceutical companies, in a market that could rival the $6 billion in annual sales for flu vaccines for years to come, analysts and healthcare investors say, Reuters reports.

So, is now a good time to buy these stocks?

Sel Hardy, senior analyst at CFRA Research, tells GOBankingRates that he sees “the news favorable for PFE and MRNA since the authorization was for those two vaccines only. I also see the potential of an emergency use authorization for the mRNA-based COVID-19 vaccine for younger children ages 5 to 11 coming soon, as another near-term catalyst.”

CFRA raised its opinion on shares of Pfizer Strong Buy from Buy, following the FDA decision.

“We think other countries might also follow suit, despite WHO’s concerns for vaccine equity, due to the rising health risks posed by the Delta variant and diminishing protection of the vaccine over time, based on recent studies,” according to a research note sent to GOBankingRates. “We also expect to see a faster regulatory approval for the vaccine for younger children ages 5 to 11 due to increasing health concerns for this unvaccinated age group, and the rapidly spreading Delta variant amid the start of a new school year.”

Building Wealth

As for Moderna, the stock fell 16% Wednesday as investors seemed to struggle to value shares that have nearly tripled in value this year, Barron’s reported, adding that the stock was up more than 300% over that period, beating the S&P 500, which climbed 18.%.

Moderna’s stock was up 1.56% this morning, at $397.51, while Pfizer’s was up 1.61%, at $48.

See: Moderna Enters the S&P Amid Delta Variant Fears – Should You Invest?
Find: Stimulus Update: New Bill Proposes Expansion of Worker Benefits on the Heels of Child Tax Credits and COVID Relief Checks

“The country has entered yet another wave of the COVID-19 pandemic, and the FDA is especially cognizant that immunocompromised people are particularly at risk for severe disease. After a thorough review of the available data, the FDA determined that this small, vulnerable group may benefit from a third dose of the Pfizer-BioNTech or Moderna Va. Today’s action allows doctors to boost immunity in certain immunocompromised individuals who need extra protection from COVID-19,” acting FDA Commissioner Janet Woodcock, said in a statement.

“As we’ve previously stated, other individuals who are fully vaccinated are adequately protected and do not need an additional dose of COVID-19 vaccine at this time. The FDA is actively engaged in a science-based, rigorous process with our federal partners to consider whether an additional dose may be needed in the future.”

Building Wealth

More From GOBankingRates

About the Author

Yaël Bizouati-Kennedy is a former full-time financial journalist and has written for several publications, including Dow Jones, The Financial Times Group, Bloomberg and Business Insider. She also worked as a vice president/senior content writer for major NYC-based financial companies, including New York Life and MSCI. Yaël is now freelancing and most recently, she co-authored  the book “Blockchain for Medical Research: Accelerating Trust in Healthcare,” with Dr. Sean Manion. (CRC Press, April 2020) She holds two master’s degrees, including one in Journalism from New York University and one in Russian Studies from Université Toulouse-Jean Jaurès, France.

Untitled design (1)
Close popup The GBR Closer icon

Sending you timely financial stories that you can bank on.

Sign up for our daily newsletter for the latest financial news and trending topics.

Loading...
Please enter an email.
Please enter a valid email address.
There was an unknown error. Please try again later.

For our full Privacy Policy, click here.